TScan Therapeutics, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-11. Between them they name 2 people, with 1 appointment and 2 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
While the Company may elect to update these forward looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law even if new information becomes available in the future.
Departing: Jason A. Amello, Chief Financial Officer, effective 2026-09-02
Departure of Certain Officers In connection with the Strategic Reorganization, effective as of September 2, 2026 (the "Effective Date"), the employment of Jason A. Amello, the Company's Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company's Chief Medical Officer, was terminated.
Departing: Leiden Dworak, Vice President, effective 2026-04-10
On March 31, 2026, Leiden Dworak notified TScan Therapeutics, Inc. (the "Company") of his decision to resign as Vice President of Finance of the Company and principal accounting officer effective April 10, 2026.
Appointed: Jason A. Amello, Chief Financial Officer, effective 2026-04-10
In connection with Mr. Dworak's resignation, the Board of Directors of the Company appointed Jason A. Amello, the Chief Financial Officer and principal financial officer of the Company, as the Company's principal accounting officer, effective April 10, 2026.
Find people with the same kind of experience as the Chief Financial Officer at TScan Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at TScan Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time TScan Therapeutics, Inc. is in the news or changes leadership.
Get an alert when TScan Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for TScan Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.